Lively Biotech has obtained optimistic suggestions from regulators on a protocol modification to its ongoing proof-of-concept scientific trial evaluating tasquinimod in sufferers with myelofibrosis, a...
The U.S. Meals and Drug Administration (FDA) has accepted PD-L1 IHC 22C3 pharmDx, Code SK006, as a companion diagnostic to assist establish sufferers with epithelial...
Pooled knowledge affirm that earlier use of Bruton tyrosine kinase (BTK) inhibitors like acalabrutinib (Calquence) could also be extra useful in sufferers with...
